Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound   Target Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound

---

Query: EC:4.6.1.1 (adenylate cyclase)
19,190 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

In aged animals and humans the pulsatile secretion of growth hormone (GH), the mean amounts of GH released over 24 h, and the response of GH to the administration of GH-releasing hormone (GHRH) are lower than in young adults. Pituitary somatotrophic cells in old male and female rats show an impaired responsiveness to GHRH, and the reduced secretion of GH in vitro is linked with a diminished stimulation of adenylate cyclase by GHRH. Pretreatment with GHRH in vivo decreases the high basal adenylate cyclase activity in old male rats. This pretreatment does not affect the rise of adenylate cyclase concentration in these rats that is subsequently induced by GHRH administration in vitro. However, it does induce a small rise in adenylate cyclase concentration in old female rats. In young rats of either sex the same GHRH schedule does not alter adenylate cyclase activity, but it does reduce the effectiveness of subsequent acute exposure to GHRH to stimulate enzymatic activity. Short-term administration of GHRH in some aged subjects increases the response of GH to a subsequent acute challenge with GHRH. However, primary or secondary alterations in somatotrophic cells are also present in aged mammals, such as a reduction in the number of GH-immunoreactive structures or post-receptor alterations. In aged rats, major alterations in brain neurotransmitters and neuropeptides are present in hypothalamic and extrahypothalamic structures, especially in catecholaminergic and acetylcholinergic neurones. These alterations are probably due to defects in neurosecretory GHRH and somatostatin neurones. GHRH synthesis is impaired in the hypothalamus of senescent male rats, as shown by a reduction in GHRH mRNA levels and GHRH-like immunoreactivity. Although the expression of somatostatin seems to decrease with age in the rat hypothalamus, secretion and activity of this hormone is increased, resulting in an altered relationship between GHRH and somatostatin gene expression and secretion. Catecholamines induce GH release in most animal species by stimulating GHRH neurones and inhibiting somatostatin-releasing neurones. Acetylcholine stimulates GH release via muscarinic receptors, and thus inhibits the effect of somatostatin neurones. In male rats of various ages, except very young rats, systemic administration of pilocarpine, an agonist of muscarinic receptors, potentiates the GH response to GHRH during the entire lifespan.(ABSTRACT TRUNCATED AT 400 WORDS)
...
PMID:Aspects of the neuroendocrine control of growth hormone secretion in ageing mammals. 810 Feb 77

The receptor for parathyroid hormone (PTH) and PTH-related protein (PTHrP) is a member of a subfamily of G-protein-coupled receptors. This subfamily includes receptors for calcitonin, secretin, vasoactive intestinal polypeptide, glucagon, and related peptides, growth hormone-releasing hormone, and pituitary adenylate cyclase activating peptide. These receptors couple agonist occupancy to activation of adenylate cyclase and, in some cases, to increases in Cai2+, but the molecular basis of signalling is unclear Mutagenesis studies of recombinant PTH/PTHrP receptors indicates that large portions of the third intracellular loop and C-terminal tail can be deleted and/or mutated without major loss of receptor-G-protein interaction, as evidenced by high affinity ligand binding and signal transduction. However, specific determinants in these domains appear to modulate the efficiency of effector activation. Further studies are needed to define the contact sites for PTH/PTHrP receptor-G-protein interaction.
...
PMID:Structure and function of the receptor for parathyroid hormone and parathyroid hormone-related protein. 816 70

Insect diuretic hormones and their receptors regulate fluid and ion secretion and thus are attractive targets for the design of novel insect control agents. A complementary DNA clone encoding a corticotropin-releasing factor-related diuretic hormone receptor from the tobacco hornworm Manduca sexta was isolated by expression cloning in COS-7 cells. The receptor consists of 395 amino acids and contains seven putative transmembrane domains. The expressed receptor binds M. sexta diuretic hormone, as well as several related insect diuretic peptides with high affinity. Furthermore, each of these peptides stimulate adenylate cyclase in COS-7 cells transfected with the receptor. The M. sexta diuretic hormone receptor is homologous to the receptors for calcitonin, secretin, vasoactive intestinal peptide, parathyroid hormone, glucagon-like peptide 1, growth hormone-releasing hormone, pituitary adenylate cyclase-activating polypeptide, and glucagon. The M. sexta diuretic hormone receptor is the first nonmammalian member of this family to be identified.
...
PMID:Expression cloning of an insect diuretic hormone receptor. A member of the calcitonin/secretin receptor family. 827 84

Despite extensive research, the biochemical abnormalities underlying the predisposition to and the pathogenesis of affective disorders remain to be clearly established. Efforts to study norepinephrine (NE) output and function have utilized biochemical assays, neuroendocrine challenge strategies, and measures of peripheral blood cell receptors; the cumulative database points to a dysregulation of the noradrenergic system. Depressed patients (in particular, melancholic, unipolar subjects) excrete disproportionately greater amounts of NE and its major extraneuronal metabolite, normetanephrine, than do controls. Depressed patients also show subsensitive neuroendocrine (growth hormone) and biochemical (inhibition of adenylate cyclase) responses to alpha 2-adrenergic agonists, suggesting that subsensitivity of nerve terminal alpha 2 autoreceptors may underlie the exaggerated plasma NE observed in response to various challenges in affective disorders. Future advances in brain imaging techniques and in the molecular biology of adrenergic receptor-coupled signal transduction systems offer promise for meaningful advances in our understanding of the pathophysiology of affective disorders.
...
PMID:Catecholamines in depression: an update. 831 9

The mechanisms responsible for the diminished lipolytic response of adipocytes to catecholamines after litter removal from lactating rats and their modulation by growth hormone have been investigated. Lactation, litter removal and growth-hormone treatment did not alter the ability of noradrenaline to activate protein kinase A (A-kinase), showing that the defect in signal transduction in rats after litter removal is after A-kinase. Litter removal had no effect on hormone-sensitive lipase activity itself, but the proportion of the lipase associated with the fat droplet was decreased; growth-hormone treatment increased hormone-sensitive lipase activity and the proportion associated with the fat droplet. In addition, a number of other adaptations in the beta-adrenergic signal-transduction system occur during the lactation cycle and in response to growth hormone treatment, including changes in receptor number, adenylate cyclase activity and cyclic AMP phosphodiesterase activity, but a defect in the ability of hormone-sensitive lipase to associate with the lipid droplet appears to be the major reason for the diminished response to catecholamines on litter removal.
...
PMID:Mechanisms involved in the adaptations of the adipocyte adrenergic signal-transduction system and their modulation by growth hormone during the lactation cycle in the rat. 838 54

The mechanism of growth hormone's (bovine growth hormone, bGH) stimulatory action on steroidogenesis was examined using ovarian tissue of spotted seatrout (Cynoscion nebulosus) in an in vitro incubation system and compared to that of a gonadotropin (human chorionic gonadotropin, hCG). Testosterone and estradiol production by seatrout ovaries in vitro were stimulated even with low concentrations of bGH (50 ng/ml), and increasing concentrations demonstrated a concentration-dependent relationship similar to that observed with hCG. The steroidogenic responses to combined treatments with bGH and hCG approximately equaled the sum of the stimulatory effects of the two hormones, possibly indicating that bGH does not potentiate the action of gonadotropin. Cyanoketone treatment of vitellogenic follicles inhibited bGH-induced estradiol production, but the stimulatory effect of bGH on the conversion of exogenous testosterone to estradiol was not altered by cyanoketone, which suggests that GH stimulates aromatase activity in addition to an earlier step in the biosynthetic pathway for estradiol production. The stimulatory effects of bGH and hCG on aromatase activity were mimicked by forskolin and dibutyryl cAMP, both of which are known to raise the intracellular level of cAMP. These results suggest that bGH- as well as hCG-induced increases in aromatase activity are mediated through adenylate cyclase-cAMP-dependent mechanism(s). The cAMP content of ovarian follicles was markedly increased within 15 min of bGH stimulation and was maximal at 1 hr, whereas steroid production did not increase significantly until 30 min and was maximal after 3 to 9 hr of incubation. The cAMP response to bGH, like that of steroid production, was concentration-dependent. The time-course and concentration-response effects of bGH on cAMP accumulation and steroid production were similar to those of hCG and forskolin, although the magnitude of the responses was less. The addition of cycloheximide or actinomycin D to the media did not affect the basal production of estradiol but completely blocked the bGH and hCG stimulation of the aromatization of exogenous testosterone to estradiol. These results suggest that the stimulatory effects of bGH and hCG on aromatase activity depend upon the synthesis of new RNA and regulatory protein(s).
...
PMID:Mechanism of stimulatory action of growth hormone on ovarian steroidogenesis in spotted seatrout, Cynoscion nebulosus. 839 59

The effect of human growth hormone-releasing hormone (hGHRH), a potent stimulator of adenylate cyclase in somatotrophs on the voltage-gated sodium current was determined by perforated patch clamp of cultured rat somatotrophs The amplitude of the voltage-gated sodium current was augmented by 65.3 +/- 20.6% (mean +/- SE, n = 7) by 10 nM hGHRH. This augmentation was reversibly blocked by 10 microM H-89 a specific inhibitor for adenosine 3',5'-cyclic monophosphate (cAMP)-dependent protein kinase. The membrane-permeant analogue of cAMP, dibutyryl cAMP (5 mM), also augmented the voltage-gated sodium current by 39.6 +/- 7.4% (n = 10). There were no effects of hGHRH or dibutyryl cAMP on steady-state inactivation of the sodium current. In contrast, in the whole cell configuration of patch clamp, no augmentation of the sodium current was observed by hGHRH or by the membrane-permeant analogue of cAMP. These results suggest that hGHRH augments the peak amplitude of the voltage-gated sodium current in rat somatotrophs via phosphorylation by cAMP-dependent protein kinase. For this augmentation, the intracellular environment must be kept relatively intact.
...
PMID:Growth hormone-releasing hormone augments voltage-gated Na+ current in cultured rat pituitary cells. 877 37

Many important advances in our understanding of the growth hormone (GH) axis have occurred during the last decade. A number of neurotransmitters and neuropeptides are implicated in the control of growth hormone-releasing hormone (GHRH) and somatostatin release; however, the role of many of these, such as serotonin, gamma-aminobutyric acid and dopamine, is still a matter of discussion. As a newly isolated hypothalamic peptide with a possible role in the control of GH secretion, pituitary adenylate cyclase activating peptide has received considerable attention. Synthetic hexapeptides that stimulate GH release (GH-releasing peptides 1, 2 and 6) have been identified. Pituitary-specific transcription factors involved in the expression of the GH gene have been identified, the GHRH receptor gene has been cloned, as well as a number of somatostatin receptor genes, and advances in our understanding of the insulin-like growth factor-binding proteins, and growth hormone-binding proteins have been made.
...
PMID:The growth hormone axis: control and effects. 880 20

Corticotropin-releasing factor (CRF) plays a major role in coordinating the endocrine, autonomic, behavioral and immune responses to stress through actions in the brain and the periphery. CRF receptors identified in brain, pituitary and spleen have comparable kinetic and pharmacological characteristics, guanine nucleotide sensitivity and adenylate cyclase-stimulating activity. Differences were observed in the molecular mass of the CRF receptor complex between the brain (58,000 Da) and the pituitary and spleen (75,000 Da), which appeared to be due to differential glycosylation of the receptor proteins. The recently cloned CRF receptor in the pituitary and the brain (designated as CRF1) encodes a 415 amino acid protein comprising seven putative membrane-spanning domains and is structurally related to the calcitonin/vasoactive intestinal peptide/growth hormone-releasing hormone subfamily of G-protein-coupled receptors. A second member of the CRF receptor family encoding a 411 amino acid rat brain protein with approximately 70% homology to CRF1 has recently been identified (designated as CRF2); there exists an additional splice variant of the CRF2 receptor with a different N-terminal domain encoding a protein of 431 amino acids. In autoradiographic studies, CRF receptors were localized in highest densities in the anterior and intermediate lobes of the pituitary gland, olfactory bulb, cerebral cortex, amygdala, cerebellum and the macrophage-enriched zones and red pulp regions of the spleen. CRF can modulate the number of CRF receptors in a reciprocal manner. For example, stress and adrenalectomy increase hypothalamic CRF secretion which, in turn, down-regulates CRF receptors in the anterior pituitary. CRF receptors in the brain and pituitary are also altered as a consequence of the development and aging processes. In addition to a physiological role for CRF in integrating the responses of the brain, endocrine and immune systems to physiological, psychological and immunological stimuli, recent clinical data implicate CRF in the etiology and pathophysiology of various endocrine, psychiatric, neurologic and inflammatory illnesses. Hypersecretion of CRF in the brain may contribute to the symptomatology seen in neuropsychiatric disorders, such as depression, anxiety-related disorders and anorexia nervosa. Furthermore, overproduction of CRF at peripheral inflammatory sites, such as synovial joints may contribute to autoimmune diseases such as rheumatoid arthritis. In contrast, deficits in brain CRF are apparent in neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease and Huntington's disease, as they relate to dysfunction of CRF neurons in the brain areas affected in the particular disorder. Strategies directed at developing CRF-related agents may hold promise for novel therapies for the treatment of these various disorders.
...
PMID:Corticotropin-releasing factor receptors: physiology, pharmacology, biochemistry and role in central nervous system and immune disorders. 883 89

We have examined the binding of radio-iodinated vasoactive intestinal peptide (VIP) to rat platelets. The binding was time- and temperature-dependent and was reversible, saturable and specific. Scatchard analysis of binding data suggested the presence of a single class of binding sites, with Kd = 2.49 +/- 0.76 nM and Bmax = 112.1 +/- 54.6 fmol/10(8) cells. Several VIP-related peptides inhibited 125I-VIP binding to rat platelets with the following order of potency: helodermin > or = VIP > peptide histidine isoleucine. Glucagon, secretin, growth hormone-releasing hormone (GHRH), and gastric inhibitory peptide (GIP) were ineffective. VIP and the other peptides increased cyclic AMP production with the same order of potency as the inhibition of binding, but the stimulation by VIP was less marked than that by prostacyclin (PGI2). We conclude that rat platelets have functional, adenylate cyclase-linked, receptors that bind preferentially to helodermin and VIP.
...
PMID:Characterization of VIP-and helodermin-preferring receptors on rat platelets. 883 17


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>

---